These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38686517)

  • 21. Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine.
    Hill LA; Abulhosn KK; Yin JF; Bamford LP
    AIDS; 2023 Mar; 37(4):605-609. PubMed ID: 36730069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.
    van Welzen BJ; Van Lelyveld SFL; Ter Beest G; Gisolf JH; Geerlings SE; Prins JM; Van Twillert G; Van Nieuwkoop C; Van der Valk M; Burger D; Wensing AMJ
    Clin Infect Dis; 2024 Jul; 79(1):189-195. PubMed ID: 38207125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV.
    Bares SH; Scarsi KK
    Curr Opin HIV AIDS; 2022 Jan; 17(1):22-31. PubMed ID: 34871188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study protocol: the ILANA study - exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritised people and older people living with HIV in the UK - a qualitative multiphase longitudinal study design.
    Farooq HZ; Apea V; Kasadha B; Ullah S; Hilton-Smith G; Haley A; Scherzer J; Hand J; Paparini S; Phillips R; Orkin CM
    BMJ Open; 2023 Jul; 13(7):e070666. PubMed ID: 37423623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
    Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
    J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection.
    Durham SH; Chahine EB
    Ann Pharmacother; 2021 Nov; 55(11):1397-1409. PubMed ID: 33593093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series.
    Kilcrease C; Yusuf H; Park J; Powell A; Rn LJ; Rn JO; Lmsw BD; Weld ED; Dooley KE; Arrington-Sanders R; Agwu AL
    AIDS Res Ther; 2022 Nov; 19(1):56. PubMed ID: 36435793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic.
    Howe ZW; Norman S; Lueken AF; Huesgen E; Farmer EK; Jarrell K; Mathis JE; Bonham KW; Hahn J
    Pharmacotherapy; 2021 Aug; 41(8):686-699. PubMed ID: 34130357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
    Rizzardini G; Overton ET; Orkin C; Swindells S; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Girard PM; Oka S; Andrade-Villanueva JF; Richmond GJ; Baumgarten A; Masiá M; Latiff G; Griffith S; Harrington CM; Hudson KJ; St Clair M; Talarico CL; Patel P; Cutrell A; Van Eygen V; D'Amico R; Mrus JM; Wu S; Ford SL; Chow K; Roberts J; Wills A; Walters N; Vanveggel S; Van Solingen-Ristea R; Crauwels H; Smith KY; Spreen WR; Margolis DA
    J Acquir Immune Defic Syndr; 2020 Dec; 85(4):498-506. PubMed ID: 33136751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
    Chounta V; Snedecor SJ; Wu S; Van de Velde N
    BMC Infect Dis; 2022 May; 22(1):428. PubMed ID: 35508986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct switch from an efavirenz-based regimen to intramuscular long-acting cabotegravir plus rilpivirine: A case report.
    Senkoro E; Bracchi M; Heskin J; Walters Y; Varadarajan M; Antoniadi C; Al-Shakarchi Y; Girometti N; Boffito M
    Int J STD AIDS; 2024 Mar; 35(4):311-313. PubMed ID: 37997937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.
    Kerrigan D; Mantsios A; Gorgolas M; Montes ML; Pulido F; Brinson C; deVente J; Richmond GJ; Beckham SW; Hammond P; Margolis D; Murray M
    PLoS One; 2018; 13(1):e0190487. PubMed ID: 29304154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience.
    Castelli A; Lanzafame M; Morra M; Bertoldi M; Delama A; Fait D; Vento S
    AIDS Res Hum Retroviruses; 2024 May; 40(5):283-285. PubMed ID: 37776179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
    Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
    Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
    Mills A; Richmond GJ; Newman C; Osiyemi O; Cade J; Brinson C; De Vente J; Margolis DA; Sutton KC; Wilches V; Hatch S; Roberts J; McCoig C; Garris C; Vandermeulen K; Spreen WR
    AIDS; 2022 Feb; 36(2):195-203. PubMed ID: 34652287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
    Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ;
    Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Demonstration Project of Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV.
    Gandhi M; Hickey M; Imbert E; Grochowski J; Mayorga-Munoz F; Szumowski JD; Oskarsson J; Shiels M; Sauceda J; Salazar J; Dilworth S; Nguyen JQ; Glidden DV; Havlir DV; Christopoulos KA
    Ann Intern Med; 2023 Jul; 176(7):969-974. PubMed ID: 37399555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long-acting injection therapies: New opportunities and challenges].
    Lee M
    MMW Fortschr Med; 2024 Jul; 166(Suppl 2):32-34. PubMed ID: 38980615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use.
    Philbin MM; Parish C; Bergen S; Kerrigan D; Kinnard EN; Reed SE; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Alcaide ML; Metsch LR
    AIDS Patient Care STDS; 2021 Jan; 35(1):23-30. PubMed ID: 33400587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use.
    Maruapula D; Moraka NO; Bareng OT; Mokgethi PT; Choga WT; Seatla KK; Kelentse N; Koofhethille CK; Zuze BJL; Gaolathe T; Pretorius-Holme M; Makhema J; Novitsky V; Shapiro R; Moyo S; Lockman S; Gaseitsiwe S
    J Antimicrob Chemother; 2023 Oct; 78(10):2489-2495. PubMed ID: 37585352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.